However, this is not the case, because suppression of the AβPP proteolytic pathway at symptomatic phase of the disease (i.e., at the stage two of AD) in human clinical trials had no effect whatsoever on the progression of AD [11,12], consistent with the autonomous operation of the pathway that produces an agent which drives the second AD stage. Here, APP is linked to Alzheimer disease.